Annual report pursuant to Section 13 and 15(d)

Supplemental Disclosures of Cash Flow Information and Noncash Investing and Financing Activities - Additional Information (Detail)

v2.4.0.8
Supplemental Disclosures of Cash Flow Information and Noncash Investing and Financing Activities - Additional Information (Detail) (USD $)
12 Months Ended 0 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2012
Apr. 30, 2014
PrimeGene
Other Significant Noncash Transactions [Line Items]        
Acquisition consideration       $ 18,761,000
Cash paid, net of cash acquired 109,180,000 0 0 6,031,000
Acquisition consideration, payable       12,730,000
Cash paid for income taxes 55,200,000 51,600,000 58,700,000  
Stock options shares of common stock exercised 1,077      
Shares of common stock surrender as a result of option exercise 733      
Fair market value of common stock surrender as a result of option exercise $ 56,000